AstraZeneca: shares fall further following rumours.

(CercleFinance.com) - AstraZeneca shares fell further on Friday as analysts respond to yesterday's rumours that group's CEO, Pascal Soriot, could soon be named as head of Israeli pharma giant Teva.


"AstraZeneca's response to date has been the understandable "We do not comment on market rumours"," Barclays analysts write in a note this morning.

"Meritable as Dr Soriot's skills are, the reaction has more to do with the inferred implication for Mystic's imminent outcome," the broker explains.

The first results of the Mystic trial - which was designed to assess the benefit of durvalumab in non-small cell lung cancer (NSCLC) - are indeed due in mid-2017.

After falling 3.5% yesterday after the news, AstraZeneca are down a further 1.7% at 4,928 pence on the London Stock Exchange this morning.

Copyright (c) 2017 CercleFinance.com. All rights reserved.